-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, E/UAv2oYx+lvj7TavJnNelJ+9R/8DakliMK6LSsmOoGAJGPQo1KB4IF0+RAXr/9E 04OCQN1O+oAWi0X67rKf7g== 0000950133-03-001137.txt : 20030331 0000950133-03-001137.hdr.sgml : 20030331 20030331134114 ACCESSION NUMBER: 0000950133-03-001137 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030331 ITEM INFORMATION: Financial statements and exhibits ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20030331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GUILFORD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000918066 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521841960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23736 FILM NUMBER: 03629026 BUSINESS ADDRESS: STREET 1: 6611 TRIBUTARY ST CITY: BALTIMORE STATE: MD ZIP: 21224 BUSINESS PHONE: 4106316300 8-K 1 w85002e8vk.htm FORM 8-K e8vk
 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 31, 2003

GUILFORD PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)

         
Delaware   0-23736   52-1841960
 
 
(State or other jurisdiction of   (Commission File Number)   (I.R.S. Employer
incorporation or organization)       Identification No.)
     
6611 Tributary Street    
Baltimore, Maryland   21224
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (410) 631-6300



(Former name or former address, if changed since last report)


Exhibit Index is on page 4.

 

 

INFORMATION TO BE INCLUDED IN THE REPORT

     
Item 7.   Financial Statements, Pro Forma Financial Information and Exhibits.
 
    (c) Exhibits
     
99.1   Written Statement of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350)
     
Item 9.   Regulation FD Disclosure

                          In connection with the Annual Report of Guilford Pharmaceuticals Inc. (the “Company”) on Form 10-K for the year ended December 31, 2002 as filed with the Securities and Exchange Commission on the date hereof, the Company filed with the Securities and Exchange Commission as correspondence the certificate required under 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002.

                         A copy of this certificate is attached hereto as Exhibit 99.1.

 

 

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    GUILFORD PHARMACEUTICALS INC.
 
Dated: March 31, 2003   By: /s/ Andrew R. Jordan
Andrew R. Jordan
Sr. Vice President, Chief Financial
Officer, and Treasurer (Principal
Financial Officer and Principal
Accounting Officer)

 

 

INDEX TO EXHIBITS

             
Exhibit            
           
Number   Exhibit Description   Page
 
 
99.1   Written Statement of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)     5  

  EX-99.1 3 w85002exv99w1.htm EXHIBIT 99.1 exv99w1

 

Exhibit 99.1

Written Statement of Chief Executive Officer and Chief Financial Officer
Pursuant to Section 906
of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

     The undersigned, the Chief Executive Officer and the Chief Financial Officer of Guilford Pharmaceuticals Inc. (the “Company”), each hereby certifies that, to his knowledge on the date hereof:

  (a)   the Annual Report on Form 10-K of the Company for the year ended December 31, 2002 filed on the date hereof with the Securities and Exchange Commission (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
  (b)   information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  /s/ Craig R. Smith, M.D.
Craig R. Smith, M.D.
Chief Executive Officer
March 31, 2003

  /s/ Andrew R. Jordan
Andrew R. Jordan
Chief Financial Officer
March 31, 2003

  -----END PRIVACY-ENHANCED MESSAGE-----